IQVIA Holdings Stock: Is IQV Outperforming the Health Care Sector?
At a glance
- $IQV today−0.15%last $264.73
- Vs industry peers+0.64 pts6-peer median −0.78% · ahead
- Since Sep 10+1.13%from the first trade after the story
- 52-week range6.9% below high$154.50 – $284.50
- Last reported profit$350.0Mquarter to Sep 30, 2026 · 10-Q
- Sector scannerCalmHealth Care
Nothing reported about iqvia across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $IQV -0.15% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
IQVIA ($IQV) slipped 0.15% to $264.73 in the latest session. Over the past month it is down 0.4%. It now sits 6.9% under the 52-week high of $284.50 and 71% above the year's low of $154.50. The high sits 84% above the low, a wide range for one year.
What the filings say
In its latest report (10-Q, filed Oct 27, 2026), $IQV earned $350.0M over the quarter to Sep 30, 2026 on revenue of $4.43B (+1.4% QoQ). Operations brought in $2.00B of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $1.52B. It carried $16.07B of debt against $2.25B of cash on Sep 30, 2026 — net debt of $13.82B. The company filed an 8-K — the form for material events — on Sep 9, 1 day before this story; it is $IQV's own account and the first thing to read. Figures are as filed with the SEC; the $IQV page has the full statements.
How much coverage it is getting
Nothing new on IQVIA has come through Wook's feeds in the last 30 days, so this is still the most recent story on it.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
For the company's side of it, read its latest SEC filings on the $IQV page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. Wook AI, at the top of the page, can work out how far $IQV is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Yahoo Finance published this on September 10, 2026. $IQV has moved +1.13% ($261.77 to $264.73). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
